FDA granted Fast Track designation for NSCLC treatment, while MAIA entered a master clinical supply agreement with Roche, leading to international trial expansion.
1 report, 1 independent
Updated Aug 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted Fast Track designation for NSCLC treatment, while MAIA entered a master clinical supply agreement with Roche, leading to international trial expansion.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- MAIA Biotechnology began clinical trials, dosing the first patient in Taiwan and screening in Europe and Asia, with Regeneron providing Libtayo.Sub-event
MAIA received Fast Track designation from the FDA for NSCLC treatment and expanded trials into Europe.1 source
Keep exploring
The entities involved
- FDA
-
Hoffmann-La Roche
Swiss healthcare company
Related events
- Both the FDA and the European Medicines Agency govern drug approval processes.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA approval expands patient access to therapies for ACCORD.
- Major pharmaceutical companies face safety questions and intense competition in the obesity drug market.
- Cardiff Oncology and Nerviano Medical Sciences are seeking FDA regulatory review for Phase 3 trials and managing a licensing dispute over onvansertib.
Coverage
Newest first; wire copies grouped- GlobeNewswireDiamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) New York, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus